FindTrial
Sign In

Deferoxamine in Aneurysmal Subarachnoid Hemorrhage trial (DASH)

Status
Not yet recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-514615-10-01
Enrollment
40
Registered
2025-01-14
Start date
Unknown
Completion date
Unknown
Last updated
2025-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subarachnoid hemorrhage

Brief summary

The presence of new ischemia at control imaging (2 weeks and 6 months)

Detailed description

Serum Ferritin, GOS-E, EQ-5D, mRS

Interventions

DRUGDeferoxamine Noridem 500mg Κόνις για ενέσιμο διάλυμα ή διάλυμα για έγχυση
DRUGNaCl 0
DRUG9%

Sponsors

Stichting Radboud universitair medisch centrum
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
The presence of new ischemia at control imaging (2 weeks and 6 months)—

Secondary

MeasureTime frame
Serum Ferritin, GOS-E, EQ-5D, mRS—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026